Litcius/Paper detail

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

Timo Vesikari, Joanne M. Langley, Nathan Segall, Brian J. Ward, Curtis Cooper, Guillaume Poliquin, Bruce R. Smith, Soren Gantt, Janet E. McElhaney, Marc Dionne, Pierre Van Damme, Isabel Leroux‐Roels, Geert Leroux‐Roels, Nathalie Machluf, Johanna N. Spaans, Bebi Yassin-Rajkumar, David E. Anderson, Vlad Popovic, Francisco Díaz‐Mitoma, Timo Vesikari, Joanne M. Langley, Soren Gantt, Marc Dionne, Janet E. McElhaney, Bruce Rankin, Carl Griffin, Mark Turner, Judith L. Kirstein, Barbara Rizzardi, Hayes Williams, Anitta Ahonen, Olli Henriksson, Benita Ukkonen, Marita Paassilta, Nathan Segall, Brian J. Ward, Curtis Cooper, Guillaume Poliquin, Bruce R. Smith, Pierre Van Damme, Isabel Leroux‐Roels, Geert Leroux‐Roels, Nathalie Machluf, Johanna N. Spaans, Bebi Yassin-Rajkumar, David E. Anderson, Vlad Popovic, Francisco Díaz‐Mitoma

2021The Lancet Infectious Diseases72 citationsDOI

Topics & Concepts

MedicineImmunogenicityVaccinationHepatitis BRandomized controlled trialInternal medicineHepatitis B virusAntigenPediatricsImmunologyVirusHepatitis B Virus StudiesVaccine Coverage and HesitancyHepatitis Viruses Studies and Epidemiology
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial | Litcius